Evidence map›Paper›PMID 36556051›Full record

ArticleJournal of clinical medicine2022

Correlation of Biomarkers of Endothelial Injury and Inflammation to Outcome in Hospitalized COVID-19 Patients.

Levy Munguía, Nayelli Nájera, Felipe de Jesús Martínez, Dylan Díaz-Chiguer, Fiacro Jiménez-Ponce, Miguel Ortiz-Flores, Francisco Villarreal, Guillermo Ceballos

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Endotheliopathy in Acute COVID-19 and Long COVID.International journal of molecular sciences · 2023
    Pooled it
  2. Review
  3. Article
  4. SARS-CoV-2 uptake and inflammatory response in senescent endothelial cells are regulated by the BSG/VEGFR2 pathway.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Levy MunguíaDirección Normativa de Salud, Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado, Mexico City 06030, Mexico.
Nayelli NájeraSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0002-6869-8762
Felipe de Jesús MartínezHospital General de Tláhuac, Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado, Mexico City 06030, Mexico.
Dylan Díaz-ChiguerDirección Normativa de Salud, Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado, Mexico City 06030, Mexico.
Fiacro Jiménez-PonceHospital General de México "Dr. Eduardo Liceaga", Mexico City 06720, Mexico.
Miguel Ortiz-FloresSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0001-6091-2448
Francisco VillarrealSchool of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Guillermo CeballosSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0003-2155-3934
Institute for Social Security and Services for State Workers · MXInstituto Politécnico Nacional · MXHospital General de México · MXUniversity of California San Diego · US

Funding

Epicatechin and derivatives to preserve muscle structure function in diabetesR01DK098717 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HENRY, ROBERT ROY, VILLARREAL, FRANCISCO J · 2014 to 2017
$1.4M
Epicatechin treatment for sarcopeniaR21AG047326 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLARREAL, FRANCISCO J · 2015 to 2015
$233k
BLRD VA I01 BX003230NIA NIH HHS R21 AG047326NIDDK NIH HHS R01 DK098717NIH HHS DoD PR150090, NIH DK98717, AG47326SIP, IPN 20220789
6 · The paper itself

Abstract

COVID-19 can trigger an intense systemic inflammation and prothrombotic state, leading to a rapid and disproportionate deterioration of lung function. An effective screening tool is essential to identify the patients at risk for severe disease. This observational study was conducted on hospitalized patients with moderate and severe COVID-19 pneumonia in a general hospital in Mexico City between 1 March 2021 and 15 March 2021. Serum samples were analyzed to explore the role of biomarkers of inflammation, coagulation, oxidative stress, and endothelial damage with the severity of the disease. Our results demonstrated that Syndecan-1 and nitrites/nitrates showed a high correlation in severely ill patients. In conclusion, COVID-19 patients with elevated levels of SDC-1 were associated with severe disease. This molecule can potentially be used as a marker for the progression or severity of COVID-19. Preservation of glycocalyx integrity may be a potential treatment for COVID-19.

Indexed as

COVID-19endothelial injuryinflammatory biomarkerssyndecan-1

Identifiers

PMID36556051
PMCPMC9785942
OpenAlexW4311612130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.